Experience with a placebo-controlled randomized clinical trial of a disease-modifying drug for osteoarthritis: the doxycycline trial.

Author(s): Brandt KD, Mazzuca SA

Affiliation(s): Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5100, USA. kbrandt@iupui.edu

Publication date & source: 2006-02, Rheum Dis Clin North Am., 32(1):217-34, xi-xii.

Publication type: Research Support, N.I.H., Extramural

Little effort has gone into the development of more effective analgesics for osteoarthritic pain. Efforts to improve symptomatic therapy for osteoarthritis have been deflected or diluted by a decision to pursue the development of disease-modifying OA drugs (DMOADs). These agents' main mechanism of action is directed not at the relief of joint pain but at slowing the progression of structural damage. This article describes the results of a recent randomized placebo-controlled designed to examine the DMOAD effect in humans of the tetracycline antibiotic doxycycline, and reviews the experience gained from other recent DMOAD trials in humans.